TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05401747

Intervention type: OTHER
Group type: OTHER
Intervention: Healthy lifestyle
Description: Nutrition consultation and teaching: A registered dietitian has the responsibility of teaching and explaining the diet. Plan: One meeting per 12 weeks. The exercise program is based on the Physical Activity Guidelines Advisory Committee and American Heart Association guideline and a modified version of Dose-Responses to Exercise Training study protocol for older adults summarized our weekly plans in detail. Plan: 2 meetings per week. Cognitive enhancement: Participants can select any of the following activities:methods requiring mental activities, physical activity, and social activity, enjoying music and our weekly dance classes (Waltz).
Study: NCT05029557

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education and telephone follow ups based on the Chronic Care Model
Description: The effects of Chronic Care Model-based education and telephone follow-up given to patients with COPD on self-efficacy and patient-reported outcomes.
Study: NCT06318845

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DHP2302R1
Description: 75 mg per dose, once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DHP2302R1
Description: 75 mg per dose, once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DHP2302R1
Description: 75 mg per dose, once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DHP2302R1
Description: 75 mg per dose, once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DHP2302R1
Description: 75 mg per dose, once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DHP2302R1
Description: 75 mg per dose, once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DHP2302R2
Description: 50 mg per dose, once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DHP2302R2
Description: 50 mg per dose, once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DHP2302R2
Description: 50 mg per dose, once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DHP2302R2
Description: 50 mg per dose, once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DHP2302R2
Description: 50 mg per dose, once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DHP2302R2
Description: 50 mg per dose, once daily
Study: NCT05675007

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Colon-delivered multivitamin supplement
Description: Colon-delivered multivitamin supplement containing the following dose of the indicated vitamin: vitamin B2 (10 mg), vitamin B3 (4.0 mg), vitamin B6 (1.4 mg), vitamin B9 (400 μg), vitamin C (200 mg) and vitamin D3 (15ug). Vitamin capsules are filled with microcrystalline cellulose and magnesium stearate up to 200 mg. Control of release in the colon is achieved by the Eudragit S 100 coating layer technology that surrounds the vitamins contained in the core capsules.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo capsule
Description: Placebo capsule containing microcrystalline cellulose and magnesium stearate up to 200 mg. Placebo capsules are coated with the Eudragit S 100 coating layer.
Study: NCT06138145

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Video
Description: Different videos were shown for Arms B and C. No Video was shown for Group A or D.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Video
Description: Different videos were shown for Arms B and C. No Video was shown for Group A or D.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Video
Description: Different videos were shown for Arms B and C. No Video was shown for Group A or D.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Survey
Description: Survey about participant's demographics, information source trust, and clinical trials knowledge. Also includes question about whether the participant is interested in enrolling in the Pediatric Trials Notification System.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Survey
Description: Survey about participant's demographics, information source trust, and clinical trials knowledge. Also includes question about whether the participant is interested in enrolling in the Pediatric Trials Notification System.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Survey
Description: Survey about participant's demographics, information source trust, and clinical trials knowledge. Also includes question about whether the participant is interested in enrolling in the Pediatric Trials Notification System.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Survey
Description: Survey about participant's demographics, information source trust, and clinical trials knowledge. Also includes question about whether the participant is interested in enrolling in the Pediatric Trials Notification System.
Study: NCT05012878

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cardiac rehabilitation - high intensity interval training (HIIT)
Description: During cardiac rehabilitation (12-weeks, 3 sessions/week), exercise training will comprise of 4x4-min high intensity aerobic intervals at a rating of perceived exertion 15-17 (hard to very hard), interspersed by a 3-min active recovery at a rating of perceived exertion 11-13 (fairly light to somewhat hard). Warm-up (4-min) and cool-down (3-min) at a light intensity.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cardiac rehabilitation - moderate intensity continuous training (MICT)
Description: During cardiac rehabilitation (12-weeks, 3 sessions/week), exercise training will comprise of 34-min of continuous aerobic exercise at a rating of perceived exertion 11-13 (fairly light to somewhat hard). Warm-up (3-min) and cool-down (3-min) at a light intensity.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Cardiac rehabilitation - control
Description: Participants will receive exercise advice in line with usual hospital discharge procedures. This involves exercise physiologists providing verbal and written information on achieving the national physical activity guidelines (150min/week of moderate intensity exercise) 60 and range of movement exercises for surgical patients with sternotomy. However, no structured or supervised exercise training program or other contact with participants will be provided after hospital discharge, to reflect the usual care process for patients that decline cardiac rehabilitation.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Cardiac rehabilitation - observational
Description: During cardiac rehabilitation (12-weeks), program frequency and exercise training protocol will align with clinical care decisions and/or patient choice rather than random assignment.
Study: NCT04126824

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triamcinolone
Description: 40 mg triamcinolone administered as a Superior Hypogastric Nerve Block (SHNB)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: 0.5% bupivacaine (20 mL) administered as a Superior Hypogastric Nerve Block (SHNB).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: 0.5% bupivacaine (20 mL) administered as a Superior Hypogastric Nerve Block (SHNB).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Iohexol contrast
Description: The appropriate amount of contrast to enable visualization of the nerve block under fluoroscopy given as a Superior Hypogastric Nerve Block (SHNB) will be administered.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Iohexol contrast
Description: The appropriate amount of contrast to enable visualization of the nerve block under fluoroscopy given as a Superior Hypogastric Nerve Block (SHNB) will be administered.
Study: NCT05628259

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tele-Nursing based Motivational Interviewing
Description: A motivational interview (MI) program based on the telenursing approach was applied to the individuals in the experimental group. In this study, the MI procedure includes eight sessions in total, with four sessions of motivational interviews by phone in the first month of the intervention and four sessions of motivational interviews by phone in the next two months for each individual. Pre-tests were collected in the first month. Afterwards, MI intervention was applied for three months. This intervention was applied to the experimental group in addition to the routine care provided by the hospital. MI application took an average of 45-60 minutes via phone call.
Study: NCT05860010

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epinephrine injection
Description: patients will be placed on left lateral position and drug will be given the caudal space

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: patients will be placed on left lateral position and drug will be given the caudal space

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bupivacaine
Description: patients will be placed on left lateral position and drug will be given the caudal space

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: patients will be placed on left lateral position and drug will be given the caudal space

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: patients will be placed on left lateral position and drug will be given the caudal space
Study: NCT05651204

Intervention type: DIAGNOSTIC_TEST
Intervention: GABA Blood Level
Description: Blood specimens will be collected by a registered phlebotomist according to hospital's specimen collection procedures.

Intervention type: DIAGNOSTIC_TEST
Intervention: GABA Blood Level
Description: Blood specimens will be collected by a registered phlebotomist according to hospital's specimen collection procedures.
Study: NCT04863183

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CELLISTEM-OA
Description: The intra-articular puncture will be performed by an orthopedic doctor specializing in knee and hip treatments. The procedure will be carried out using sterile technique, after cooling the skin with local ice.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone acetonide
Description: The intra-articular puncture will be performed by an orthopedic doctor specializing in knee and hip treatments. The procedure will be carried out using sterile technique, after cooling the skin with local ice.
Study: NCT05459090

Intervention type: OTHER
Intervention: ex-vivo study
Description: ex-vivo experiments in tissue slices obtained from biopsies
Study: NCT06437431

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: glenzocimab
Description: Two vials (2x500 mg) of glenzocimab should be administered concomitantly for eligible patients for a total dose of 1g of glenzocimab as an IV infusion over 6 hours, with 1/4 of the dose administered by a 15-minutes bolus and 3/4 of the dose administered by 5h45minutes continuous infusion.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo of glenzocimab is 0.9% NaCl for IV administration. It is supplied for clinical trial use in vials of 50 mL. Two vials of placebo should be administered concomitantly for eligible patients. The administration scheme will be the same as in the experimental arm.
Study: NCT06208956

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: In the dexmedetomidine group, dexmedetomidine is infusion intravenously with a loading dose of 0.5 μg kg-1 for 10 min, then infusion at 0.3 μg kg-1 h-1 according to the ideal body weight of the patient until the end of colonoscopy. During the whole process, maintenance Ramsay score of 3 to 4. Propofol 10 mg will be administrated as the rescue dose if body movement occur during colonoscopy.

Intervention type: DRUG
Group type: OTHER
Intervention: Propofol
Description: Propofol is administrated 1 mg kg-1 intravenously, then titrated given by 0.5 mg kg-1 until Ramsay score reach 3. During the whole process, propofol is given intermittently to maintain Ramsay score 3 to 4. If body movement happen, propofol 10mg will be administrated every time.
Study: NCT04191460

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cRGD-ZW800-1.
Description: Injection of cRGD-ZW800-1 within 48 hours before imaging/surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cRGD-ZW800-1.
Description: Injection of cRGD-ZW800-1 within 48 hours before imaging/surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cRGD-ZW800-1.
Description: Injection of cRGD-ZW800-1 within 48 hours before imaging/surgery
Study: NCT06394934

Intervention type: BEHAVIORAL
Intervention: Healthscan App
Description: Participants will use the Healthscan mobile application to monitor and record their daily blood pressure at home. The app allows participants to enter their BP measurements, which are then used to calculate blood pressure variability (BPV). The app's use is intended as a non-invasive, practical tool for patient self-management and longitudinal health monitoring in hypertensive individuals.
Study: NCT05369819

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: . Patients of the midazolam group will be treated with midazolam premedication (3 cc mixture of 0.035 mg/kg midazolam and normal saline; maximum midazolam dose, 3 mg) intravenously a waiting area 3 minutes before transportation to an operating room

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Control group patients are treated with 3 cc normal saline in a waiting area 3 minutes before transportation to an operating room
Study: NCT05038137

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Time restricted feeding
Description: Participants will eat all food during a self selected 8 hour eating window prior to 8:00 PM.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Participants will have a daily eating period equal to or greater than 12 hours.
Study: NCT05528263

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Standardized acupuncture protocol 1-2 times a week for 12 weeks (a total of 14 sessions).
Study: NCT05568940

Intervention type: DRUG
Intervention: Tibolone 2.5 Mg Oral Tablet
Description: Tibolone oral therapy for 2-3 months: All participants will take a Tibolone 2.5 mg tablet orally daily, at the same time each day, following a scheduled, luteal-phase injection of leuprolide acetate 11.25mg intramuscular (IM).
Study: NCT05528263

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nature scenery with a relaxation exercise
Description: Watch nature scenery videos with a relaxation exercise guide 1-2 times a week for 12 weeks (a total of 14 sessions)
Study: NCT05297266

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IscAlert
Description: Insertion of a CO2- and temperature sensor in the distal part of the replanted extremity
Study: NCT06428214

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Restylane Shaype
Description: Injection

Intervention type: DEVICE
Group type: OTHER
Intervention: Restylane Shaype
Description: Injection

Intervention type: DEVICE
Group type: OTHER
Intervention: Restylane Shaype
Description: Injection

Intervention type: DEVICE
Group type: OTHER
Intervention: Restylane Defyne
Description: Injection

Intervention type: DEVICE
Group type: OTHER
Intervention: Restylane Defyne
Description: Injection

Intervention type: DEVICE
Group type: OTHER
Intervention: Restylane Lyft lidocaine
Description: Injection
Study: NCT04536220

Intervention type: DIAGNOSTIC_TEST
Intervention: Endoscopic Ultrasound (EUS), Fine Needle Aspiration
Description: Endoscopic Ultrasound (EUS), Fine Needle Aspiration, which are routine clinical operations

Intervention type: DIAGNOSTIC_TEST
Intervention: Endoscopic Ultrasound (EUS), Fine Needle Aspiration
Description: Endoscopic Ultrasound (EUS), Fine Needle Aspiration, which are routine clinical operations
Study: NCT04196257

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BP1001-A (Liposomal Grb2 Antisense Oligonucleotide)
Description: Dose escalation of BP1001-A intravenously (IV), twice weekly for 4 weeks (28-day cycle) for 6 cycles.
Study: NCT06299254

Intervention type: OTHER
Intervention: Placebo-Natural History
Description: Half of the participants will receive a placebo (i.e., motivational/verbal) cue before and after an experimental session in which they will perform several lifts.~Half of the participants will receive no placebo before and after an experimental session in which they will perform several lifts.

Intervention type: OTHER
Intervention: Placebo-Natural History
Description: Half of the participants will receive a placebo (i.e., motivational/verbal) cue before and after an experimental session in which they will perform several lifts.~Half of the participants will receive no placebo before and after an experimental session in which they will perform several lifts.
Study: NCT05690256

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resilience Clinic
Description: A psychoeducational caregiver-child intervention based in primary care, designed to mitigate toxic stress and promote child resilience. Participants engage in 6 weekly visits in primary care using an interactive curriculum based in the evidence-based Circle of Security Parenting along with mindfulness principles.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced primary care
Description: In addition to usual pediatric primary care, enhanced primary care (the control condition for this study) provides navigational services to link to community resources based on screening for unmet social needs (e.g., food insecurity, housing, financial strain).
Study: NCT04196257

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BP1001-A (Liposomal Grb2 Antisense Oligonucleotide) with paclitaxel
Description: Dose expansion of BP1001-A IV twice weekly (Maximum tolerated dose or Maximum admistered dose) plus paclitaxel IV weekly for 4 weeks (28-day cycle) for 6 cycles.
Study: NCT05516563

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: EDucation and eXercise intervention
Description: The exercise programme includes 3 key streams:~1. Low-load isometric abduction~2. Functional loading~3. Abductor loading: Graduated abductor loading, designed to improve load tolerance by applying progressively higher loads across the abductor muscles. Daily exercise will be completed three days a week at a 'hard' to 'very hard' level, alternating with three 'light' days and one rest day. The clinic day will constitute one of the 'hard' days.~Education will be delivered via a 20 minute video which focusses on understanding and managing lateral hip pain ( ie pain associated with gluteal tendinopathy). Education will also be tailored to each patient on attendance with the physiotherapist at the 6 clinic visits
Study: NCT06299371

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adebrelimab
Description: Adebrelimab IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel for injection (albumin bound)
Description: paclitaxel for injection (albumin bound) IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin or Carboplatin
Description: Cisplatin or Carboplatin IV
Study: NCT05027360

Intervention type: DRUG
Intervention: SNP - Sodium Nitroprusside
Description: The primary objective of our study is to assess the efficacy and safety of SNP as part of the treatment regimen of AHF patients and to identify predictors of efficacy.
Study: NCT04922047

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tislelizumab and BCG
Description: Tislelizumab 200 mg administered by intravenous infusion every 3 weeks in first year and continue to second year based on physician choose. BCG 120 mg induction therapy administered via intravesical instillation (once weekly for 6 weeks). BCG induction therapy is followed by maintenance therapy (once weekly for 3 weeks at months 3, 6, 12, 18, 24m).
Study: NCT05735210

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Polso™ Watch blood pressure measurement compared to a reference blood pressure measurement
Description: The referenced blood pressure measurements are taken by dual auscultators.
Study: NCT05488756

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Group 1
Description: Physical therapy agents and isometric exercise training will be applied to the patients. These will be administered a combination of transcutaneous electrical nerve stimulation, ultrasound, a hot pack, and isometric training 3 times a week for 4 weeks by the physical therapist.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group 2
Description: Physical therapy agents and deep cervical flexor muscle training will be applied to the patients. These will be administered a combination of transcutaneous electrical nerve stimulation, ultrasound, a hot pack, and muscle training 3 times a week for 4 weeks by the physical therapist. Training of the craniocervical flexor muscles is going to be focused on the deep flexor muscles such as longus capitis and longus colli muscles, making neck flexion, not the head.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group 3
Description: Physical therapy agents and core stabilization training will be applied to the patients. These will be administered a combination of transcutaneous electrical nerve stimulation, ultrasound, a hot pack, and stabilization training 3 times a week for 4 weeks by the physical therapist. These exercises will be performed for 10 repetitions with 10 seconds of contraction and 5 seconds of relaxation.
Study: NCT05821270

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ashtanga Vinyasa Yoga Supta
Description: Ashtanga (asta - eight, anga - parts); Vinyasa (freely sequenced practice); Yoga (practice for evolution); Supta (closed eyes)
Study: NCT05490706

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Bodyweight interval exercise
Description: Performing 15 minutes of bodyweight interval exercise after dinner at home by following a video
Study: NCT05830110

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active Vibrotactile Coordinated Reset
Description: Gloves providing vibrotactile coordinated reset stimulation

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham vibrotactile coordinated reset
Description: Gloves providing sham vibrotactile coordinated reset stimulation
Study: NCT05490706

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Walking
Description: Performing a 30 minute minute walk after dinner at home